GlassScriptPhysician profile
Rachel E Hippeard
NPI 1548926348
$2,654.61
in general payments reported to CMS, 2019-2025
30 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $810 · 2023: $484 · 2024: $551 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.02 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.20 | 2022-2025 | |
| Novo Nordisk INC | $447.94 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $245.90 | 2023-2025 | |
| Lilly USA, LLC | $186.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $163.07 | 2022-2025 | Prolia, Evenity, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $150.44 | 2022 | |
| Merck Sharp & Dohme LLC | $105.73 | 2022-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $103.87 | 2022-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $96.02 | 2022-2025 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $78.43 | 2022-2023 | Xarelto |
| Seqirus USA INC | $78.34 | 2025 | Fluad, Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $57.11 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $56.74 | 2024-2025 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $56.70 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $54.90 | 2022-2025 | Shingrix, Arexvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.50 | 2023-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $35.66 | 2022-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $23.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.93 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $22.23 | 2025 | Gemtesa |
| Philips North America LLC | $21.81 | 2024 | (Ck6) Holter |
| Idorsia Pharmaceuticals US INC | $20.46 | 2023 | Quviviq |
| Corium, LLC | $19.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.06 | 2022 | |
| Almatica Pharma LLC | $16.30 | 2022 | |
| Exact Sciences Corporation | $16.19 | 2025 | The Cologuard Plus Collection Kit |
| Amneal Pharmaceuticals LLC | $14.80 | 2025 | Unithroid |
| Currax Pharmaceuticals LLC | $13.34 | 2022 | |
| Watermark Medical, INC. | $13.17 | 2024 | |
| Phathom Pharmaceuticals, INC. | $9.87 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Hippeard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.